Berkley and Jensen Acid Controller Maximum Strength and Pexidartinib Hydrochloride
Determining the interaction of Berkley and Jensen Acid Controller Maximum Strength and Pexidartinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: famotidine
Brand name: Pepcid, Heartburn Relief, Pepcid AC, Pepcid AC Maximum Strength, Pepcid AC Chewable Tablets, Pepcid Oral Suspension
Synonyms: n.a.
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Berkley and Jensen Acid Controller Maximum Strength-Pfizerpen
- Berkley and Jensen Acid Controller Maximum Strength-Pharaon Tea
- Berkley and Jensen Acid Controller Maximum Strength-Pharmorubicin Pfs
- Berkley and Jensen Acid Controller Maximum Strength-Phazyme
- Berkley and Jensen Acid Controller Maximum Strength-Phazyme Liquid Gas Relief, Maximum Strength
- Berkley and Jensen Acid Controller Maximum Strength-Phena-Plus
- Pexidartinib Hydrochloride-Berkley and Jensen Acid Reducer Maximum Strength
- Pexidartinib Hydrochloride-Beser
- Pexidartinib Hydrochloride-Beser Lotion
- Pexidartinib Hydrochloride-Besponsa
- Pexidartinib Hydrochloride-Beta HC
- Pexidartinib Hydrochloride-Beta-Carotene